Efficacy of Glucose-Lowering Drugs for Young-Onset Type 2 Diabetes: A Meta-Analysis of Individual Participant Data from Randomized Control Trials

Young-onset type 2 diabetes means being diagnosed with type 2 diabetes before the age of 40. Type 2 diabetes is a long-term condition where the body cannot properly control the level of sugar (glucose) in the blood. This happens because the body does not make enough insulin, or because the insulin it makes does not work well. Insulin is a hormone made by the pancreas that helps move sugar from the blood into the body’s cells, where it is used for energy. When insulin does not work properly, sugar stays in the blood instead of entering the cells, leading to high blood sugar levels.

Over time, high blood sugar can damage blood vessels and organs throughout the body. This can lead to serious health problems such as heart disease, kidney disease, nerve damage, vision problems, and early death if diabetes is not well controlled. People who develop type 2 diabetes at a young age often experience these complications earlier and more severely than those diagnosed later in life.

Keeping blood sugar levels within a healthy range is one of the most important ways to prevent or delay these complications. Many medications are available to help lower blood sugar, but there is limited information on how well these treatments work in younger people with type 2 diabetes. This is because people with young-onset diabetes have often been underrepresented in past research studies.

The goal of this study is to find out which blood sugar-lowering medications work best for people with young-onset type 2 diabetes compared to those diagnosed later in life. We will combine information from many previous studies so that enough younger individuals can be included to draw meaningful conclusions. By comparing blood sugar levels after people take different medications, we aim to identify the most effective treatments.

This research will help doctors make better treatment decisions for younger people with type 2 diabetes. Identifying the best medications may improve blood sugar control, reduce hospital visits, prevent serious complications, and help people with young-onset diabetes live longer and healthier lives.

早发性2型糖尿病（young-onset type 2 diabetes）指在40岁前被确诊为2型糖尿病的病症。2型糖尿病是一种长期慢性代谢性疾病，患者机体无法正常调控血液中葡萄糖（glucose）的水平。其致病机制为机体胰岛素分泌不足，或是所产生的胰岛素无法正常发挥作用。胰岛素是由胰腺分泌的一种激素，可协助血液中的葡萄糖进入机体细胞并转化为能量供机体使用。当胰岛素无法正常发挥功能时，葡萄糖会滞留在血液中而非进入细胞，进而导致血糖水平升高。

随着病程进展，持续升高的血糖会损伤全身各处的血管与器官。若糖尿病未得到良好控制，可引发心脏病、肾病、神经损伤、视力障碍等严重健康问题，甚至导致过早死亡。相较于晚年确诊的2型糖尿病患者，早发性2型糖尿病患者往往更早出现并发症，且病情更为严重。

将血糖水平维持在健康范围内，是预防或延缓此类并发症的核心措施之一。目前已有多种降糖药物可供临床使用，但针对年轻群体2型糖尿病患者的治疗效果相关研究证据较为有限。究其原因，既往相关研究中早发性糖尿病患者的入组比例普遍偏低。

本研究的核心目标为：对比不同降糖药物在早发性2型糖尿病患者与晚年确诊的2型糖尿病患者中的治疗效果，筛选出最适合早发性患者的降糖方案。我们将整合多项既往研究的数据，以纳入足够数量的年轻患者，从而得出具有临床意义的研究结论。通过对比患者服用不同降糖药物后的血糖水平变化，本研究旨在明确最优治疗药物。

本研究成果将助力临床医生为年轻2型糖尿病患者制定更为合理的治疗方案。明确最优降糖药物可改善患者的血糖控制情况，减少住院频次，预防严重并发症，最终帮助早发性2型糖尿病患者延长寿命、提升生活质量。